Researchsemaglutideliraglutidemetabolic syndromecardioprotection

Rat study finds liraglutide and semaglutide limit ischemia-reperfusion damage

Both GLP-1 agonists improved post-ischemic contractility and oxidative stress markers in Wistar rats with diet- and streptozotocin-induced metabolic syndrome.

By Priya Raman · Science Reporter

Sep 18 20:00 ETSource: Medical sciences (Basel, Switzerland)

The wire

01Male Wistar rats with metabolic syndrome received saline, liraglutide or semaglutide for six weeks; both drugs improved post-ischemic myocardial contractility and relaxation in a Langendorff ex vivo ischemia/reperfusion model.
02Treated animals showed lower superoxide anion levels, enhanced antioxidant defence, and reduced myocardial hypertrophy and collagen deposition, plus improved hepatic and pancreatic histology.
03This is an animal model with semaglutide showing the stronger body-weight effect; the authors frame the cardioprotection as potential, and no human endpoints were tested.

From the source

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome
Medical sciences (Basel, Switzerland) · 2026 Sep 19 · Ravić MP, Srejović IM, Andjić MM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42783463/